SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 29, 2008 (March 28, 2008)
GUIDED THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware (State or Other Jurisdiction of Incorporation) |
0-22179 (Commission File Number) |
58-2029543 (IRS Employer Identification No.) |
4955
Avalon Ridge Pkwy, Suite 300 |
30071 |
Registrant's Telephone Number, Including Area Code: (770) 242-8723
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 7.01. REGULATION FD DISCLOSURE. | ||||||||
| SIGNATURES | ||||||||
Item 7.01. Regulation FD Disclosure.
On March 28, 2008, Guided Therapeutics, Inc. entered into a development and license to option agreement with an undisclosed multi-national diabetes company to evaluate a continuous glucose monitor for people with diabetes. Under terms of the agreement, the larger company has a defined amount of time to license the technology during which time it will pay Guided Therapeutics an option to license fee and conduct development work.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GUIDED THERAPEUTICS, INC. | ||||
/s/ MARK L. FAUPEL |
||||
| By: | Mark L. Faupel, Ph.D. | |||
| President & CEO | ||||
| Date: April 29, 2008. | ||||